BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

Core Points - BioLineRx Ltd. has received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, as the closing bid price for its American Depositary Shares (ADSs) has been below USD $1.00 for 30 consecutive trading days [1][2] - The company has a grace period of 180 calendar days, until November 11, 2024, to regain compliance with the minimum bid price [3] - If the bid price reaches or exceeds USD $1.00 for at least 10 consecutive business days before the deadline, Nasdaq will notify the company of compliance [3] - Should the company fail to regain compliance by the deadline, it may be eligible for an additional 180 days to cure the deficiency if it meets other listing requirements [4] - The company's business operations remain unaffected by the notification, and it will continue to monitor the bid price of its ADSs [5] Company Overview - BioLineRx is a commercial stage biopharmaceutical company focused on developing therapies for oncology and rare diseases [7] - The company's first approved product is APHEXDA® (motixafortide), indicated for stem cell mobilization in multiple myeloma [7] - BioLineRx is advancing a pipeline of investigational medicines targeting sickle cell disease, pancreatic cancer, and other solid tumors [7]